Gender differences in the slow delayed (I Ks) but not in inward (I K1) rectifier K + currents of canine Purkinje fibre cardiac action potential: Key roles for I Ks, β-adrenoceptor stimulation, pacing rate and gender

British Journal of Pharmacology

Volumn 147, Issue 6, 2006, Pages 653-660

  Abi Gerges, Najah ^a   Small, Ben G ^a   Lawrence, Chris L ^a   Hammond, Tim G ^a   Valentin, Jean Pierre ^a   Pollard, Chris E ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

adrenoceptor stimulation; Action potential duration; Gender; Inward rectfier cardiac K + current; Purkinje fibre; Slow delayed rectifier cardiac K + current

Indexed keywords

BARIUM CHLORIDE; BETA ADRENERGIC RECEPTOR; CHROMANOL 293B; INWARDLY RECTIFYING POTASSIUM CHANNEL; ISOPRENALINE; POTASSIUM CHANNEL; SLOW DELAYED RECTIFYING POTASSIUM CHANNEL; UNCLASSIFIED DRUG;

ACTION POTENTIAL DURATION; ADOLESCENT; ANIMAL CELL; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BETA ADRENERGIC STIMULATION; CONTROLLED STUDY; DOG; DRUG EFFECT; FEMALE; GENDER; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HEART PACING; HEART PACING RATE; HEART RATE; HEART REPOLARIZATION; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; PURKINJE FIBER; SEX DIFFERENCE; TIME;

ACTION POTENTIALS; ADRENERGIC BETA-AGONISTS; ANIMALS; BARIUM COMPOUNDS; CARDIAC PACING, ARTIFICIAL; CHLORIDES; CHROMANS; DOGS; ELECTRIC STIMULATION; FEMALE; ISOPROTERENOL; MALE; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; POTASSIUM CHANNELS, VOLTAGE-GATED; PURKINJE FIBERS; RECEPTORS, ADRENERGIC, BETA; SEX FACTORS; SULFONAMIDES; TIME FACTORS;

EID: 33645101254     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706491     Document Type: Article

References (34)

1. ABI-GERGES, N., PHILP, K., POLLARD, C., WAKEFIELD, I., HAMMOND, T.G. & VALENTIN, J.P. (2004a). Sex differences in ventricular repolarization: from cardiac electrophysiology to Torsades de Pointes. Fundam. Clin. Pharmacol., 18, 139-151.
2. ABI-GERGES, N., SMALL, B.G., LAWRENCE, C.L., HAMMOND, T.G., VALENTIN, J.P. & POLLARD, C.E. (2004b). Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br. J. Pharmacol., 142, 1255-1264.
3. ANON. (1997). Committee for Proprietary Medical Products (CPMP). Points to consider: The assessment of the potential of QT interval prolongation by non-cardiovascular medicinal products. The European Agency for the evaluation of medicinal products. London, 17 December. Reference CPMP/ICH/986/96.
4. ANON. (2005a). ICH E14 Note for guidance on the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. London, 25 May. Reference CHMP/ICH/2/04.
5. ANON. (2005b). ICH S7B Note for guidance on the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. London, 25 May. Reference CHMP/ICH/423/02.
6. BILICZKI, P., VIRAG, L., IOST, N., PAPP, J.G. & VARRO, A. (2002). Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve. Br. J. Pharmacol., 137, 361-368.
7. + current, on repolarization in human and guinea pig ventricular myocytes. Cardiovasc. Res., 38, 441-450.
8. CHIANG, C.E. (2004). Congenital and acquired long QT syndrome. Current concepts and management. Cardiol. Rev., 12, 222-234.
9. Ks channels by HMR 1556. Naunyn. Schmiedebergs Arch. Pharmacol., 362, 480-488.
10. GRALINSKI, M.R. (2003). The dog's role in the preclinical assessment of QT interval prolongation. Toxicol. Pathol., 31 (Suppl), 11-16.
11. HAN, W., WANG, Z. & NATTEL, S. (2001). Slow delayed rectifier current and repolarization in canine cardiac Purkinje cells. Am. J. Physiol. Heart Circ. Physiol., 280, H1075-H1080.
12. JAMES, A.F., CHOISY, S.C.M. & HANCOX, J.C. (2005). Recent advances in understanding sex differences in cardiac repolarization. Prog. Biophys. Mol. Biol., in press (doi: 10.1016/j.pbiomolbio.2005.05.010).
13. KEATING, M.T. & SANGUINETTI, M.C. (2001). Molecular and cellular mechanisms of cardiac arrhythmias. Cell, 104, 569-580.
14. LENGYEL, C., DEZSI, L., BILICZKI, P., HORVATH, C., VIRAG, L., IOST, N., NEMETH, M., TALOSI, L., PAPP, J.G. & VARRO, A. (2004). Effect of a neuroprotective drug, eliprodil on cardiac repolarisation: importance of the decreased repolarisation reserve in the development of proarrhythmic risk. Br. J. Pharmacol., 143, 152-158.
15. Ks) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. Br. J. Pharmacol., 132, 101-110.
16. + channels from guinea-pig cardiomyocytes. J. Physiol., 532, 115-126.
17. LIU, X.K., KATCHMAN, A., DRICI, M.D., EBERT, S.N., DUCIC, I., MORAD, M. & WOOSLEY, R.L. (1998). Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J. Pharmacol. Exp. Ther., 285, 672-679.
18. Ks channel blockers in vitro. J. Pharmacol. Toxicol. Methods, 51, 81-90.
19. NAKAGAWA, M., OOIE, T., OU, B., ICHINOSE, M., TAKAHASHI, M., HARA, M., YONEMOCHI, H. & SAIKAWA, T. (2005). Gender differences in autonomic modulation of ventricular repolarization in humans. J. Cardiovasc. Electrophysiol., 16, 278-284.
20. NATTEL, S. & QUANTZ, M.A. (1988). Pharmacological response of quinidine-induced early afterdepolarizations in canine Purkinje fibres: insights into underlying ionic mechanisms. Cardiovasc. Res., 22, 808-817.
21. NATTEL, S. & SINGH, B.N. (1999). Evolution, mechanisms, and classification of antiarrhythmic drugs: focus on class III actions. Am. J. Cardiol., 84, 11R-19R.
22. PLASTER, N.M., TAWIL, R., TRISTANI-FIROUZI, M., CANUN, S., BENDAHHOU, S., TSUNODA, A., DONALDSON, M.R., IANNACCONE, S.T., BRUNT, E., BAROHN, R., CLARK, J., DEYMEER, F., GEORGE JR, A.L., FISH, F.A., HAHN, A., NITU, A., OZDEMIR, C., SERDAROGLU, P., SUBRAMONY, S.H., WOLFE, G., FU, Y.H. & PTACEK, L.J. (2001). Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell, 105, 511-519.
23. REDFERN, W.S., CARLSSON, L., DAVIS, A.S., LYNCH, W.G., MACKENZIE, I., PALETHORPE, S., SIEGL, P.K., STRANG, I., SULLIVAN, A.T., WALLIS, R., CAMM, A.J. & HAMMOND, T.G. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res., 58, 32-45.
24. RODRIGUEZ, I., KILBORN, M.J., LIU, X.K., PEZZULLO, J.C. & WOOSLEY, R.L. (2001). Drug-induced QT prolongation in women during the menstrual cycle. JAMA, 285, 1322-1326.
25. SCHREIECK, J., WANG, Y., GJINI, V., KORTH, M., ZRENNER, B., SCHOMIG, A. & SCHMITT, C. (1997). Differential effect of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B. J. Cardiovasc. Electrophysiol., 8, 1420-1430.
26. SHIMIZU, W. & ANTZELEVITCH, C. (1998). Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of β-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation, 98, 2314-2322.
27. SHUBA, Y.M., DEGTIAR, V.E., OSIPENKO, V.N., NAIDENOV, V.G. & WOOSLEY, R.L. (2001). Testosterone-mediated modulation of HERG blockade by proarrhythmic agents. Biochem. Pharm., 62, 41-49.
28. Ks in canine ventricular myocytes. J. Physiol., 551 (Part 3), 777-786.
29. STRAUS, S.M.J.M, STURKENBOOM, M.C.J.M, BLEUMINK, G.S., DIELEMAN, J.P, VAN DER LEI, J., DE GRAEFF, P.A., KINGMA, J.H. & STRICKER, B.H.CH. (2005). Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur. Heart J., 26, 2007-2012.
30. SUN, Z.Q., THOMAS, G.P. & ANTZELEVITCH, C. (2001). Chromanol 293B inhibits slowly activating delayed rectifier and transient outward currents in canine left ventricular myocytes. J. Cardiovasc. Electrophysiol., 12, 472-478.
31. TAMARGO, J., CABALLERO, R., GOMEZ, R., VALENZUELA, C. & DELPON, E. (2004). Pharmacology of cardiac potassium channels. Cardiovasc. Res., 62, 9-33.
32. Ks in dog ventricular muscle and Purkinje fibre repolarization. J. Physiol., 523 (Part 1), 67-81.
33. Ks to canine ventricular repolarization: key role for β-adrenergic receptor stimulation. Circulation, 107, 2753-2760.
34. + currents in the heart. Am. J. Physiol. Heart Circ. Physiol., 285, H1641-H1649.